NJ Bio, Inc. Wins Best CRO Award at 15th Annual World ADC Conference
Media
Arvind Jay Dixit
E-mail: info@njbio.com
NJ Bio, Inc., a leading contract research organization (CRO), is honored to be awarded the Best CRO Award for the 4th consecutive year at the prestigious Annual World ADC in San Diego, California. Being recognized four times in a row as the Best CRO, the NJ Bio Team has shown its sustainable and steadfast commitment to quality, timeliness, and competitive pricing while advancing preclinical and clinical development of ADCs for clients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113635083/en/
NJ Bio, a Leading CRO Wins the Best CRO Award 2024 for the Fourth Consecutive Year in a Row at the World ADC Conference (Photo: Business Wire)
The Annual World ADC Conference unites thousands of ADC enthusiasts from across the globe. This event promotes innovation through knowledge exchange and shared insights from industry leaders. A highlight of the conference is the prestigious World ADC Awards, which celebrates outstanding achievements and significant contributions in ADC development, recognizing the individuals and teams that have made a positive impact in the field. One of the categories for the Awards is the Best CRO Award, which NJ Bio co-shared with PPD, Inc., a subsidiary of Thermo Fisher Scientific.
NJ Bio’s journey from being a runner-up in 2020 to holding this top honor four years in a row underscores its dedication towards innovation and growth. Over the past year, the company has expanded its service offerings to include GMP capabilities for early-phase clinical trials. The company's commitment to providing the latest technologies to its clients has driven its growth and positioned it as a comprehensive, one-stop solution for global clients. Recent partnerships with industry leaders like Lotte Biologics and Charles River Laboratories have strengthened its service platform, creating a seamless integration of complementary services that drive enhanced outcomes. With a growing client base that now includes over 150 clients worldwide, NJ Bio is a reliable partner for accelerating client programs.
Reflecting on emerging trends in ADC development, NJ Bio is driving progress by offering novel, customized linker-payload solutions. Unlike standard "copy-paste" approaches that repurpose validated linker-payloads, which often underperform in clinical trials, NJ Bio’s platform offers tailored solutions for specific therapeutic requirements. "A one-size-fits-all approach does not work for ADCs,” noted Dr. Naresh Jain, CEO of NJ Bio. “These therapies must be customized to optimize clinical outcomes and success."
About NJ Bio
NJ Bio, Inc., is a leading Contract Research Organization (CRO)/ Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, NJ, with additional chemistry facilities in Bristol, PA and Mumbai, India, providing integrated chemistry and biology services to companies in the biotech and pharmaceutical sectors. The NJ Bio team has robust expertise in bioconjugation, synthetic organic chemistry, protein-based biopharmaceuticals, and GMP manufacturing that enables clients to receive customized ADC solutions that could speed up their discovery and development. For more information about our services, please visit www.njbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113635083/en/
